Markets:

Overview

News

Currencies

International

Treasuries

Abivax SA - American Depositary Shares (NQ:ABVX)

119.53 -3.70 (-3.00%)

Streaming Delayed Price Updated: 11:52 AM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Abivax SA - American Depositary Shares

< Previous 1 2 3 4 Next >

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? ↗

January 02, 2026

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?

Via The Motley Fool

Topics Regulatory Compliance

Could This Potential Move Boost Eli Lilly's Prospects? ↗

December 31, 2025

The stock already looks unstoppable, and this move won't hurt its momentum.

Via The Motley Fool

The 2025 Growth Postgame: Analyzing the AI Supercycle and Preparing for the 2026 'Agentic' Pivot

December 26, 2025

As the final trading days of 2025 wind down, the global investment community has entered a period of intense reflection. This year’s market was defined by a breathtaking "tale of two halves," where...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

How Abivax Went From Biotech Nobody To M&A Bullseye After A Single Blockbuster Readout This Year ↗

December 24, 2025

A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality.

Via Stocktwits

Nasdaq, S&P 500 Futures Head Into Christmas Eve With Caution: Why ASTS, DVAX, ABVX, PATH, GOOGL Are On Traders' Radar Today ↗

December 24, 2025

Markets are moving from a record-setting close into a thin, holiday-shortened Christmas Eve session.

Via Stocktwits

Topics ETFs Stocks

The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave

December 23, 2025

As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results...

Via MarketMinute

Topics Intellectual Property

Why Abivax Stock Was on Fire Today ↗

December 22, 2025

Investors were excited about the possibility of a buyout with a high price tag.

Via The Motley Fool

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗

December 22, 2025

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

Via The Motley Fool

Topics Regulatory Compliance

Abivax to be Added to Nasdaq Biotechnology Index

December 18, 2025

From Abivax

Via GlobeNewswire

The Great Rotation: Small-Cap Growth Surges as Investors Ditch Defensive Safety for Post-Fed Gains

December 18, 2025

The financial markets are witnessing a historic "Great Rotation" this December, as the era of defensive posturing and mega-cap concentration appears to be giving way to a broad-based growth rally....

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings

December 17, 2025

From Abivax

Via GlobeNewswire

Abivax Presents Third Quarter 2025 Financial Results

December 15, 2025

From Abivax

Via GlobeNewswire

2 Under-the-Radar Stocks That Have Soared This Year ↗

December 09, 2025

These companies are worth your attention.

Via The Motley Fool

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗

December 09, 2025

A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.

Via The Motley Fool

Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? ↗

December 09, 2025

Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down.

Via The Motley Fool

Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets ↗

December 09, 2025

A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story.

Via The Motley Fool

Topics Regulatory Compliance

6 Healthcare Stocks With Strong Upward Momentum ↗

November 18, 2025

Via Benzinga

This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗

November 17, 2025

A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗

November 17, 2025

This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.

Via The Motley Fool

Topics Regulatory Compliance

Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗

November 17, 2025

A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗

November 17, 2025

One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.

Via The Motley Fool

This Brinker International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

November 06, 2025

Via Benzinga

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis

November 03, 2025

From Abivax

Via GlobeNewswire

Tilray Brands Posts Upbeat Results, Joins Byrna Technologies, Delta Air Lines And Other Big Stocks Moving Higher On Thursday ↗

October 09, 2025

Via Benzinga

AMD To Rally More Than 47%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

October 07, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 06, 2025

Via Benzinga

Why Is Abivax Stock Trading Higher On Monday? ↗

October 06, 2025

Abivax said Phase 3 trials showed obefazimod improved clinical outcomes in ulcerative colitis, meeting key endpoints with no new safety concerns.

Via Benzinga

Top 1% Biotech Abivax Surges On 'Compelling' Results In A Highly Watched Disease ↗

October 06, 2025

The company is working on a treatment for a form of inflammatory bowel disease, a highly watched disease area.

Via Investor's Business Daily

Topics Government

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

October 06, 2025

From Abivax

Via GlobeNewswire

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

October 05, 2025

From Abivax

Via GlobeNewswire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.